SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes
Xiancong Fang, Rong Li, Shengbin Liu, Xiaomin Zou, Yanling Zhong, Yalun Yang · 2026
Read SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes by Xiancong Fang, Rong Li, Shengbin Liu, Xiaomin Zou, Yanling Zhong, Yalun Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585633.txt.
Description
Xiancong Fang and co-authors compared two classes of diabetes drugs in a meta-analysis in two thousand twenty-six. Both classes lower blood sugar in type 2 diabetes, by different routes. The team weighed sugar control, weight change, and genital infection risk across randomized trials.
Ten trials were pooled. Low-dose drugs from the first class matched the second class on sugar control, while high-dose beat it. Both doses cut body weight more, by roughly two kilograms. But genital infections were about four times more likely with the first class at either dose. The authors advise matching drug choice to each patient's sugar targets, weight, and infection risk.
Catalog record
| CREATOR | Xiancong Fang, Rong Li, Shengbin Liu, Xiaomin Zou, Yanling Zhong, Yalun Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |